01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 conducted in the USA retatrutide triple agonist glp-1 gip
Description
Can Novo Nordisks pipeline transform obesity treatment
Total time: 5-7 minutes including preparation and hold time
Others don't tolerate the medication or don't respond results are individual
Did you know
[DOI] [PMC free article] [PubMed] [Google Scholar] 42.Bower R.L., Yule L., Rees T.A., et al
[DOI] [PubMed] [Google Scholar] 31.Wjcik P, Ggotek A, arkovi N, Skrzydlewska E
